Yes, an Annual COVID-19 Vaccine Booster is Recommended for Immunocompetent Individuals
Immunocompetent adults and children aged ≥5 years should receive 1 dose of the updated 2024-2025 COVID-19 vaccine annually, with adults aged ≥65 years recommended to receive 2 or more doses of the updated vaccine. 1, 2
Vaccination Schedule by Age Group
Adults Aged 18-64 Years (Immunocompetent)
- 1 dose of 2024-2025 COVID-19 vaccine (Moderna, Pfizer-BioNTech, or Novavax for those ≥12 years) 1
- Administer at least 8 weeks after the last COVID-19 vaccine dose 1
- This represents an annual update to match circulating variants
Adults Aged ≥65 Years (Immunocompetent)
- 2 or more doses of updated 2024-2025 vaccine 2
- This enhanced recommendation reflects higher risk for severe disease in older adults
- Timing follows the same ≥8 week interval between doses 1
Children and Adolescents (Immunocompetent)
- Ages 5-11 years: 1 dose of 2024-2025 vaccine (Moderna or Pfizer-BioNTech) 1
- Ages ≥12 years: 1 dose of 2024-2025 vaccine (Moderna, Novavax, or Pfizer-BioNTech) 1
- Ages 6 months-4 years: Multi-dose series depending on vaccination history 1
Key Clinical Reasoning
The ACIP voted 11-0 (with one abstention) in June 2024 to recommend annual COVID-19 vaccination for all persons aged ≥6 months 1. This recommendation is structured as a yearly update similar to influenza vaccination, where the vaccine composition is updated to match circulating variants (currently JN.1 and KP.2 lineages) 1.
The rationale for annual vaccination in immunocompetent individuals includes:
- Waning immunity: Research demonstrates that vaccine effectiveness against hospitalization declines from 62% at 7-59 days post-vaccination to 24% by 120-179 days in immunocompetent adults 3
- Variant evolution: Significant reductions in humoral responses occur against new circulating variants compared to previous vaccine strains 4
- Sustained protection against severe outcomes: Despite declining effectiveness against infection, protection against critical outcomes (ICU admission, death) remains more durable 3
Important Caveats
Timing Considerations
- If someone received a previous COVID-19 vaccine dose, wait at least 8 weeks before administering the 2024-2025 vaccine 1
- The recommendation is for annual vaccination, but the specific timing should align with seasonal patterns (typically fall/winter in the Northern Hemisphere)
Special Populations
- Immunocompromised individuals have separate, more intensive recommendations with additional doses 1
- Pregnant individuals should follow standard immunocompetent recommendations unless they have immunocompromising conditions
Vaccine Choice
- For those aged ≥12 years who are vaccine-naive and choose Novavax, 2 doses are required (3-8 weeks apart) 1
- Otherwise, any FDA-approved or authorized 2024-2025 vaccine is acceptable
Evidence Quality
The recommendation is based on high-quality guideline evidence from the CDC's Advisory Committee on Immunization Practices published in September 2024 [1-2] and reinforced by the 2025 adult immunization schedule 2. This represents the most current authoritative guidance and supersedes previous recommendations. The supporting research demonstrates measurable clinical benefit, with number needed to vaccinate estimates ranging from 44-615 to prevent one hospitalization depending on age and risk factors 5.